Results 51 to 60 of about 14,175 (232)
B cells and systemic sclerosis interstitial lung disease
Interstitial lung disease is an important complication of systemic sclerosis (SSc‐ILD) with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to FDA‐approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune ...
Nina Goldman+2 more
wiley +1 more source
Pharmacomicrobiomics is an emerging field due to important microbiome effects on pharmacokinetics and clinical outcomes. However, the application of this knowledge remains limited. Mycophenolic acid (MPA) is the primary active metabolite of the immunosuppressant, mycophenolate mofetil (MMF).
Abdelrahman Saqr+4 more
wiley +1 more source
Immunosuppressant prescription pattern and trend in kidney transplantation: A multicenter study in Korea. [PDF]
The actual prescription pattern of immunosuppressive agents in kidney transplantation is unclear.We investigated the pattern and trend of immunosuppressive treatment for kidney transplant patients in South Korea.
Ji-Yeun Chang+11 more
doaj +1 more source
A solid phase extraction-high-performance liquid chromatography-tandem Orbitrap high resolution mass spectrometry (HPLC-Orbitrap HRMS) method was established for the determination of 12 mycotoxins (ochratoxin A, ochratoxin B, aflatoxin B1, aflatoxin B2 ...
Donghui Luo+8 more
doaj +1 more source
Granulomatosis with polyangiitis (GPA) is an autoimmune disease affecting mainly small blood vessels. B-cells are important in the GPA pathogenesis as precursors of autoantibody-producing cells but likely also contribute (auto)antibody-independently ...
Anouk von Borstel+7 more
doaj +1 more source
Mycophenolic acid (MPA) is the active metabolite of the immunosuppressant drug mycophenolate mofetil (MMF), which is commonly prescribed after organ transplantation in conjunction with other immunosuppressants. MMF therapy is monitored to balance therapeutic efficacy with minimizing adverse effects associated with high serum concentrations.
Jesse C. Seegmiller+4 more
openaire +3 more sources
ABSTRACT Background Biologics and Janus kinase inhibitors (JAKi) are two advanced systemic treatment options for patients with atopic dermatitis (AD). The decision to initiate one of these therapies is complex and may be driven by many factors.
Eric L. Simpson+12 more
wiley +1 more source
Background Mycophenolic acid (MPA) treatment requires therapeutic drug monitoring to improve the outcome after organ transplantation. The aim of this study was to compare two methods, a particle enhanced turbidimetric inhibition immunoassay (PETINIA) and
Masafumi Kikuchi+10 more
doaj +1 more source
ABSTRACT Autophagy is a highly conserved intracellular process involved in maintaining homeostasis and in the degradation of damaged organelles and external pathogens. Nature provides complex and varied reservoirs of scaffolds and chemical entities that may have a pivotal role in the search for new therapeutic leads.
Ilaria Cursaro+5 more
wiley +1 more source
This pooled analysis of 5337 atopic eczema patients from seven TREAT registries shows variability and consistency in data collection, provides key baseline insights and demonstrates the feasibility of harmonized real‐world data. It lays the foundation for future TREAT Taskforce studies on treatment outcomes, supporting cross‐border research to guide ...
A. H. Musters+141 more
wiley +1 more source